20-Hydroxyecdysone

The sarcopenia market remains largely untapped with no approved drug therapies in major markets, despite significant unmet medical needs in an aging global population.

New preclinical data shows that combining BIO101 with GLP-1 receptor agonists significantly improved mobility and grip strength in diet-induced obese mice, addressing a critical gap in obesity treatment.

Biophytis SA has published positive Phase II SARA-INT clinical trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle, demonstrating clinically meaningful improvement in the 400-meter walk test.

Biophytis SA has entered into a co-development agreement with AskHelpU, China's largest ALS patient association, to evaluate the efficacy of BIO101 in treating Amyotrophic Lateral Sclerosis (ALS). This partnership leverages Biophytis' drug development expertise and AskHelpU's deep understanding of ALS, aiming to advance BIO101 through preclinical and potentially larger-scale clinical trials. ALS, a severe neuromuscular disease with no current cure, affects thousands globally, highlighting the significance of this collaborative effort.

Biophytis presented its OBA program featuring BIO101 (20-hydroxyecdysone) at the 17th SCWD International Congress, highlighting its potential to mitigate muscle loss induced by GLP-1RA therapies in obese patients.